Cynomolgus / Rhesus macaque LRRC15 Protein, His Tag (MALS verified)

Cat. No. / Size
Price
Availability
Qty
LR5-C52H3-100ug
$360.00
In Stock - Delivery in 1-2 business days
LR5-C52H3-1mg (500ug X 2)
$2,380.00
In Stock - Delivery in 1-2 business days
LR5-C52H3
Sub-Total :
$ 0
0
Add to Cart
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
0
Add to Cart
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

Leucine-rich repeat-containing protein 15, LRRC15, LIB, hLib

Source

Cynomolgus / Rhesus macaque LRRC15 Protein, His Tag (LR5-C52H3) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 538 (Accession # A0A2K5UKB6-1). In the region Tyr 22 - Gly 538, the amino acid sequences of Cynomolgus and Rhesus macaque LRRC15 are identical.

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 59.9 kDa. The protein migrates as 75-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.